Quantcast
Menu
Save, make, understand money

Experienced Investor

Neil Woodford tops August’s most-bought fund list

Joanna Faith
Written By:
Joanna Faith
Posted:
Updated:
02/09/2015

Neil Woodford’s eponymous Equity Income fund was investors’ most popular fund in August for the third month running, according to data from the Share Centre. 

 

AXA Framlington Biotech and Polar Capital Healthcare Opportunities bagged the second and third spots, while four FTSE trackers also made it into August’s top 10.

Sheridan Admans, investment research manager at the Share Centre, said: “The CF Woodford Equity Income fund is the number one choice for investors for the third month running. The manager of this fund is extremely popular and highly regarded by investors for the consistency of his investment approach, which should stand out during this time of market volatility.

“The Polar Capital Healthcare Opportunities fund has once again been a popular trade for investors. While advances in medical and healthcare technology continue at a rapid pace, the offering will provide investors with not only exposure to the sector, but also significant geographical exposure to the US given the dominance of this market.

“The Vanguard FTSE All Share Index trust, HSBC FTSE 250 Index trust, Legal & General UK Index trust and the Blackrock UK Equity Tracker fund have all been successful with our investors throughout August. These four unit trusts focus on replicating the performance of various UK FTSE indices. Having four tracker funds is unprecedented in comparison to our previous monthly reports. This could be the result of investors losing confidence in active management strategies, or looking for more cost effective ways of gaining access to a diverse range of UK companies.”

Other funds in the top 10 include Marlborough Special Situations, F&C Navigator Boutiques fund and Aberdeen MM Constellation trust. 

“The Marlborough Special Situations fund, managed by Giles Hargreave, is an interesting choice from investors this month. This fund seeks and identifies companies that are going through difficult times but have good recovery prospects. With a typically large risk associated, these types of funds are not for the faint-hearted and should never make up more than a small percentage of an investors overall portfolio.

“The Framlington Biotech Fund has been a prevalent choice for investors this month. It aims to provide long-term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomics and medical industries worldwide. The fund is approximately 85% invested in US equities, with top holdings including Celgene Corp and Biogen Inc.

“With a primary objective of achieving capital growth, the F&C Navigator Boutiques fund is in our investors’ top ten. The fund managers invest in other collective or closed end arrangements (also known as fund of funds), with top classifications within North American and European equities.

“Holding its place in the top ten for the second month in a row, Aberdeen MM Constellation trust is also one for investors this month. With a view to achieve long term capital growth, the fund invests predominantly in financial

August’s top traded funds from The Share Centre:

Position Fund
1 CF Woodford Equity Income fund
2 AXA Framlington Biotech fund
3 Polar Capital Healthcare Opportunities fund
4 Legal & General UK Index trust
5 HSBC FTSE 250 Index trust
6 Marlborough Special Situations fund
7 Vanguard FTSE All Share Index trust
8 Blackrock UK Equity Tracker fund
9 F&C Navigator Boutiques fund
10 Aberdeen MM Constellation trust

[article_related_posts]